Our Research Domains
Advancing science across six critical therapeutic areas to address unmet medical needs.
Oncology
Our oncology research program focuses on developing novel targeted therapies and immunotherapeutic approaches for solid tumors and hematological malignancies. Through precision medicine and advanced biomarker-driven trial designs, we aim to improve patient outcomes across a wide range of cancer types.
Immunology
Our immunology division investigates the complex mechanisms of immune response to develop breakthrough treatments for autoimmune disorders, allergic diseases, and immune deficiencies. We leverage cutting-edge monoclonal antibody technology and immune checkpoint modulation.
Neuroscience
MedHubs neuroscience research addresses critical unmet needs in neurological and psychiatric disorders. Our pipeline includes novel treatments for neurodegenerative diseases, mood disorders, and chronic pain through innovative mechanisms of action.
Infectious Diseases
Our infectious disease research combats emerging pathogens and antibiotic-resistant bacteria through next-generation antivirals, novel antibiotics, and vaccine platforms. We maintain rapid response capabilities for pandemic preparedness and global health security.
Rare Diseases
The rare diseases program at MedHubs is dedicated to developing transformative therapies for patients with genetic and orphan diseases. Using gene therapy, enzyme replacement, and RNA-based approaches, we bring hope to underserved patient populations.
AI-Driven Drug Discovery
Our AI-driven drug discovery platform combines machine learning, molecular simulations, and vast chemical libraries to accelerate the identification and optimization of novel drug candidates. This approach significantly reduces development timelines and improves success rates.
Latest Clinical Trials
MH-AI-501: AI-Designed Kinase Inhibitor in Solid Tumors
A Phase I dose-finding study of a first-in-class kinase inhibitor identified through AI-driven molecular screening. This trial evaluates safety, tolerability, and recommended Phase II dose in patients with advanced solid tumors.
AI-Driven Drug Discovery
MH-RARE-101: Gene Therapy for Spinal Muscular Atrophy Type II
A single-arm, open-label Phase I/II study to evaluate the safety and preliminary efficacy of an AAV9-based gene therapy vector in pediatric patients with Spinal Muscular Atrophy Type II.
Rare Diseases
MH-INF-402: Phase II Broad-Spectrum Antiviral for Respiratory Viruses
A randomized, placebo-controlled Phase II study evaluating the efficacy and safety of a novel broad-spectrum antiviral agent for the treatment of acute respiratory viral infections including influenza and RSV.
Infectious Diseases
Recent Publications
Novel Targeted Therapy Demonstrates Significant PFS Improvement in EGFR-Mutant NSCLC
Chen L, Williams M, Rodriguez A, Park S, et al.
The New England Journal of Medicine
This landmark Phase III trial demonstrated that MH-ONC-301 in combination with standard chemotherapy significantly improved progression-free survival compared to chemotherapy alone in patients with EGFR-mutant advanced NSCLC, with a manageable safety profile.
Machine Learning-Guided Drug Discovery: A New Paradigm for Kinase Inhibitor Development
Thompson R, Nakamura K, Singh D, et al.
Nature Reviews Drug Discovery
This review article describes the AI-driven approach used by MedHubs to identify and optimize novel kinase inhibitors, achieving a 40% reduction in lead optimization time compared to traditional methods.
Anti-IL-17 Antibody Therapy: Phase II Results in Psoriatic Arthritis
Patel N, Johansson E, Kim Y, Garcia M, et al.
The Lancet Rheumatology
Interim results from the MH-IMM-205 trial show that the novel anti-IL-17 antibody achieves ACR50 responses in 68% of patients at week 24, with significant improvements in skin and joint manifestations.
